Written question asked by Guto Bebb (Conservative) on Monday, 18 January 2016, in the House of Commons. It was due for an answer on Friday, 29 January 2016 (named day). It was answered by George Freeman (Conservative) on Friday, 29 January 2016 on behalf of the Department of Health.
Nivolumab
- Question
-
To ask the Secretary of State for Health, what information his Department holds on the effects of nivolumab on one year survival rates for lung cancer.
- Answer
-
Nivolumab is currently marketed in the European Union under the brand name Opdivo.
The data available when Opdivo was licensed in 2015 indicated overall survival among patients given the product was around nine months, whereas among the patients given docetaxel, another cancer medicine, it was six months.
Secondary information
- Type
- Written question
- Reference
- 22970
- Session
- 2015-16
- Subjects
- Lung cancer Mortality rates Nivolumab
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2016-07-05 20:15:16 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2015-16/22970
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2015-16/22970
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2015-16/22970